Clinical Research Directory
Browse clinical research sites, groups, and studies.
Carvedilol in HF With Preserved EF
Sponsor: Seoul National University Bundang Hospital
Summary
Beta-blockers improve clinical outcomes in heart failure and reduced ejection fraction (HFrEF); but not in those with preserved EF. Global longitudinal strain (GLS) is a prognostic factor independent of left ventricular ejection fraction (LVEF). In a retrospective with 1969 patients with HF and LVEF of ≥40%, beta-blocker was associated with improved survival in those with low GLS (GLS \<14%), but not in those with GLS ≥14%. In this prospective, randomized clinical study, the investigators will assess the effect of slow-release carvedilol in patients with HFpEF and hypertension. The primary endpoint is the time-averaged proportional changes in NT-proBNP level and GLS change from baseline to month 6.
Official title: Slow-release CArvedilol in Patients With REduced Strain and Preserved Ejection Fraction Heart Failure (CARE-preserved HF): A Prospective Randomized, Double-Blinded, Multicenter Study
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
63
Start Date
2021-11-17
Completion Date
2026-01-08
Last Updated
2026-05-19
Healthy Volunteers
No
Interventions
Carvedilol
patients randomized to carvedilol group will receive carvedilol-SR.
Placebo
patients randomized to placebo group will receive placebo.
Locations (2)
Samsung Medical Center
Seoul, Il-won, South Korea
Wonju Severance Christian Hospital
Wŏnju, WONJU, South Korea